XT
DSGN icon

XTX Topco’s Design Therapeutics DSGN Stock Holding History

XTX Topco’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$324K Sell
22,383
-38,556
-63% -$481K ﹤0.01% 2851
2026
Q1 		$648K Buy
60,939
+25,655
+73% +$260K 0.01% 1786
2025
Q4 		$331K Buy
35,284
+23,416
+197% +$183K 0.01% 1978
2025
Q3 		$89.4K Buy
+11,868
New +$59.4K ﹤0.01% 2048
2025
Q1 		– Sell
-48,424
Closed -$299K – 2560
2024
Q4 		$299K Buy
+48,424
New +$280K 0.02% 1224
2024
Q2 		– Sell
-15,257
Closed -$61.5K – 2000
2024
Q1 		$61.5K Buy
+15,257
New +$40.7K 0.01% 1442
2023
Q4 		– Sell
-38,472
Closed -$90.8K – 1709
2023
Q3 		$90.8K Buy
38,472
+27,673
+256% +$129K 0.02% 1196
2023
Q2 		$68K Buy
+10,799
New +$66.1K 0.01% 1205

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

XTX Topco's DSGN Position: Q2 2026 in Review

XTX Topco reduced its Design Therapeutics (DSGN) stake by 63% in Q2 2026, selling an estimated $481K and leaving 22,383 shares worth $324K. The position accounts for ﹤0.01% of the portfolio, ranked #2851.

XTX Topco first reported a position in DSGN in Q2 2023 and has held it in 8 quarters since. The position peaked at $648K in Q1 2026. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • XTX Topco held 22,383 shares of Design Therapeutics worth $324K as of Q2 2026.
  • XTX Topco sold 38,556 Design Therapeutics shares in Q2 2026, an estimated $481K.
  • Design Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #2851 holding.
  • XTX Topco first reported a position in Design Therapeutics in Q2 2023 and has held it in 8 quarters since.
  • XTX Topco's Design Therapeutics position peaked at $648K in Q1 2026.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.